Desipramine binding to noradrenaline reuptake sites in cardiac sympathetic neurons in man in vivo

Author： Malizia A.L. Melichar J.K. Rhodes C.G. Haida A. Reynolds A.H. Jones T. Nutt D.J.

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.391, Iss.3, 2000-03, pp. : 263-267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of noradrenaline and selective noradrenaline reuptake inhibition in depression

By Brunello N. Mendlewicz J. Kasper S. Leonard B. Montgomery S. Nelson J.C. Paykel E. Versiani M. Racagni G.

European Neuropsychopharmacology, Vol. 12, Iss. 5, 2002-10 ,pp. : 461-475

Elsevier

Access to resources Recommend Favorite

Reboxetine: the first selective noradrenaline re-uptake inhibitor

By Kasper S. Giamal N.E. Hilger E.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 771-782

Informa Healthcare

Access to resources Recommend Favorite

Uncompetitive inhibition of [ 3 H]1,3-di-o-tolyl-guanidine-defined binding sites by desipramine, propranolol and alprenolol in rat brain

By Shirayama Y. Takahashi K. Nishikawa T.

European Journal of Pharmacology, Vol. 331, Iss. 2, 1997-07 ,pp. : 319-323

Elsevier

Access to resources Recommend Favorite

GABA receptors and benzodiazepine binding sites modulate hippocampal acetylcholine release in vivo

By Moor E. DeBoer P. Westerink B.H.C.

European Journal of Pharmacology, Vol. 359, Iss. 2, 1998-10 ,pp. : 119-126

Elsevier

Access to resources Recommend Favorite

Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder

By Kratochvil Christopher J Vaughan Brigette S Harrington Martin J Burke William J

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 7, 2003-07 ,pp. : 1165-1174

Informa Healthcare

Access to resources Recommend Favorite